What is the future of CCR5 antagonists in rheumatoid arthritis?

scientific article published on 30 March 2012

What is the future of CCR5 antagonists in rheumatoid arthritis? is …
instance of (P31):
editorialQ871232
scholarly articleQ13442814

External links are
P356DOI10.1186/AR3775
P932PMC publication ID3446428
P698PubMed publication ID22494450
P5875ResearchGate publication ID223975768

P50authorTsutomu TakeuchiQ40949081
P2093author name stringHideto Kameda
P2860cites workMaraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trialQ36084912
Chemokine and chemokine receptor blockade in arthritis, a prototype of immune-mediated inflammatory diseases.Q37943107
CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial.Q42943397
Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexateQ42956746
Overcoming hurdles in developing successful drugs targeting chemokine receptorsQ46441158
Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptorQ74477278
Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritisQ28742993
CC chemokine receptor 5 (CCR5) desensitization: cycling receptors accumulate in the trans-Golgi networkQ34438951
Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritisQ35012157
P433issue2
P407language of work or nameEnglishQ1860
P921main subjectrheumatoid arthritisQ187255
P304page(s)114
P577publication date2012-03-30
P1433published inArthritis Research and TherapyQ15757229
P1476titleWhat is the future of CCR5 antagonists in rheumatoid arthritis?
P478volume14

Reverse relations

cites work (P2860)
Q99408059C-C chemokine receptor type 5 links COVID-19, rheumatoid arthritis, and Hydroxychloroquine: in silico analysis
Q50920198CCR5delta32 in systemic lupus erythematosus: implications for disease susceptibility and outcome in a Brazilian population.
Q38172960Chemokine receptor modeling: an interdisciplinary approach to drug design
Q90642824Role of Chemokines and Chemokine Receptors in Rheumatoid Arthritis
Q47126167The HIV co-receptor CCR5 regulates osteoclast function.
Q41945153The multiple chemokine-binding bovine herpesvirus 1 glycoprotein G (BHV1gG) inhibits polymorphonuclear cell but not monocyte migration into inflammatory sites.
Q61443001The potential risks of C-C chemokine receptor 5-edited babies in bone development

Search more.